ImmunityBio, Inc. - Common Stock (NQ:IBRX)

ImmunityBio Launches Phase 2 Chemotherapy-Free CAR-NK Cell Therapy Trial with ANKTIVA® (ResQ215B) in Indolent Lymphomas

February 02, 2026

From ImmunityBio

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of ImmunityBio, Inc. - IBRX

January 27, 2026

From Pomerantz LLP

Via GlobeNewswire

IBRX Stock Extends Rally On FDA Feedback For ANKTIVA Bladder Cancer Filing ↗

January 20, 2026

Stock Market Today, Jan. 20: ImmunityBio Soars Again After FDA Outlines Resubmission Path for ANKTIVA in Bladder Cancer ↗

January 26, 2026

On Jan. 20, 2026, investors weigh ImmunityBio’s sharp rally on new FDA feedback around its bladder cancer plans.

IBRX Stock Gains Pre-Market After A Volatile Trading Session Following Phase 2 Glioblastoma Trial Update: Retail Backs ImmunityBio’s Cancer Research ↗

Topics Stocks

January 26, 2026

Patrick Soon Shiong, ImmunityBio’s founder, took to X on Saturday to clarify what the update signified.

Nasdaq, S&P 500 Futures Open The Week On Edge As Earnings, Tariffs, Fed Decision Loom: Why META, NVDA, RVMD, USAR Are On Traders' Radar Today ↗

Topics Death ETFs

January 26, 2026

Topics Economy Stocks

$5 Stocks: NDRA, IBRX, MOVE, RVLY Drawing Attention Watch Now!

January 25, 2026

Via AB Newswire

Why IBRX Stock Is One Of The Biggest Pre-Market Movers Today ↗

January 16, 2026

IBRX Stock Continues Rally — What’s Driving The Optimism Today? ↗

January 15, 2026

Today, Jan. 23, 2026, profit taking and fresh glioblastoma survival data weighed on a soaring biotech stock.

Stock Market Today, Jan. 23: ImmunityBio Falls After Gaining Over 200% in a Month ↗

January 23, 2026

IBRX Stock Sees Volatile Session – ImmunityBio’s Update In Phase 2 Glioblastoma Trial Sparks Buzz ↗

Topics Stocks

January 23, 2026

ImmunityBio stated that it has not yet achieved median survival in patients receiving Anktiva + CAR-NK treatment in the trial.

ImmunityBio Reports Median Overall Survival Not Yet Reached and Lymphopenia Reversed in Recurrent Glioblastoma Patients Receiving ANKTIVA® Plus CAR-NK, Chemo-Free Therapy

Topics Death

January 23, 2026

On Jan. 21, 2026, the market weighed ImmunityBio’s skyrocketing share price, surging volume, and the company's heavily-shorted stock.

Stock Market Today, Jan. 21: ImmunityBio Rises Again As Short-Sellers Face Losses ↗

January 21, 2026

Stock Market Today, Jan. 20: ImmunityBio Soars Again After FDA Outlines Resubmission Path for ANKTIVA in Bladder Cancer ↗

Topics Stocks

January 20, 2026

On Jan. 20, 2026, investors weigh ImmunityBio’s sharp rally on new FDA feedback around its bladder cancer plans.

ImmunityBio Advances Regulatory Discussions with FDA on Potential Resubmission Path for ANKTIVA® in BCG-Unresponsive Papillary Bladder Cancer

Topics Stocks

Which stocks are most active on Tuesday? ↗

January 20, 2026

Via Chartmill

January 20, 2026

Nasdaq, S&P 500 Futures Slide As Trump Ramps Up Greenland Threats: Why NFLX, CRML, TSLA, VERO, SRXH Are On Traders' Radar Today ↗

January 20, 2026

Retail sentiment on Stocktwits has flipped bearish on SPY and QQQ amid elevated message volumes and rising volatility.

The company outlined progress across multiple cancer programs following last week's series of clinical and regulatory updates.

Topics Artificial Intelligence ETFs Economy

Why Is ImmunityBio Stock Back In Retail Spotlight Today? ↗

January 19, 2026

Nasdaq, S&P 500 Futures Slide On Greenland Tensions: Why NVDA, MU, IBRX, CRML And VERO Are On Traders’ Radar Today ↗

January 19, 2026

Stock Market Today, Jan. 16: ImmunityBio Soars After Anktiva Revenue Jumps 700 Percent Year Over Year ↗

Topics Stocks

January 16, 2026

Explosive Anktiva sales, new cancer data, and fresh approvals are rapidly redefining this immunotherapy story, today, Jan. 16, 2026.

It has been an incredible week of positive news for ImmunityBio.

Topics Stocks

Which stocks are experiencing notable movement on Friday? ↗

January 16, 2026

Via Chartmill

Why ImmunityBio Stock Is Skyrocketing Again Today ↗

January 16, 2026

ImmunityBio Announces Durable Complete Response of 15 Months with a Chemotherapy-Free CD19 CAR-NK Cell Therapy in Waldenstrom Lymphoma

Curious about the most active stocks on Friday? ↗

January 16, 2026

Via Chartmill

Keep an eye on the top gainers and losers in Friday's session. ↗

January 16, 2026

Via Chartmill

Friday's session: gap up and gap down stocks ↗

January 16, 2026

Via Chartmill

January 16, 2026

ImmunityBio Advances First-Line BCG Naive NMIBC Program with Enrollment Exceeding Expectations and Positive Interim Analysis for ANKTIVA® Plus BCG

January 16, 2026

On Jan. 15, 2026, investors took note of Anktiva's explosive sales ramp, its geographic expansion potential, and a possible new indication.

Stock Market Today, Jan. 15: ImmunityBio Surges After Anktiva Revenue Jumps 700% ↗

January 15, 2026